Daily imaging used to track cancer tumor changes can allow for more rapid radiation treatment adaptation, according to a study published Sept. 30 in International Journal of Radiation Oncology-Biology ...

Glioblastoma, the most aggressive malignant brain tumor in adults, is not an isolated lesion, but a disease that destabilizes ...

A new study shows the potential power of imaging paired with radiation to shape treatment for glioblastoma patients in real time. The study, led by researchers at Sylvester Comprehensive Cancer Center ...

Patients with Glioblastoma (GBM), a highly aggressive malignant brain tumor, have an extremely poor prognosis due to a lack of viable treatment choices. Since being named the “breakthrough of the year ...

Glioblastoma, the most common and most aggressive brain tumor type in adults, remains difficult to treat because it can ...

FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.

The study, led by Eric A. Mellon, M.D., Ph.D. and Kaylie Cullison, Ph.D., at Sylvester Comprehensive Cancer Center, is the first to quantify tumor changes in glioblastoma patients receiving MRI-guided ...

Telix Pharmaceuticals ( (AU:TLX)) has issued an announcement. Telix Pharmaceuticals has resubmitted a New Drug Application to the U.S. FDA for TLX101-Px (Pixclara), an F-18 FET PET imaging agent ...

Disrupted brain fluid clearance in the hemisphere opposite the tumor emerges as a strong independent predictor of survival in patients with IDH wild-type glioblastoma. Glioblastoma—the most aggressive ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. While rare, malignant brain tumors often have poor outcomes Nearly half of all malignant ...